{"id":"in-open-label-phase-treatment-with-tofacitinib","rwe":[],"tags":[],"safety":{"drugInteractions":[{"drug":"Warfarin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Rivaroxaban","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Apixaban","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Dabigatran","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Pantoprazole","action":"Avoid","effect":"Decreased tofacitinib exposure"},{"drug":"Ketoconazole","action":"Monitor","effect":"Increased tofacitinib exposure"},{"drug":"Rifampicin","action":"Avoid","effect":"Decreased tofacitinib exposure"},{"drug":"Phenobarbital","action":"Avoid","effect":"Decreased tofacitinib exposure"},{"drug":"Carbamazepine","action":"Avoid","effect":"Decreased tofacitinib exposure"},{"drug":"Phenytoin","action":"Avoid","effect":"Decreased tofacitinib exposure"},{"drug":"St. John's Wort","action":"Avoid","effect":"Decreased tofacitinib exposure"},{"drug":"CYP3A4 inducers","action":"Avoid","effect":"Decreased tofacitinib exposure"},{"drug":"CYP3A4 inhibitors","action":"Monitor","effect":"Increased tofacitinib exposure"}],"contraindications":["Active infections, including tuberculosis and opportunistic infections; severe hepatic impairment; known hypersensitivity to tofacitinib or any of its excipients; concurrent use with potent CYP3A4 inhibitors or inducers"]},"trials":[],"aliases":[],"company":"Pfizer","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=in-open-label-phase-treatment-with-tofacitinib","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:56:18.742471+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:56:25.503620+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-19T23:56:18.761238+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=in-open-label-phase-treatment-with-tofacitinib","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:56:26.163748+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Janus Kinase (JAK) inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:56:27.190317+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2103743/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:56:27.077244+00:00"}},"allNames":"in open-label phase: treatment with tofacitinib","offLabel":[],"timeline":[],"aiSummary":"Tofacitinib is a medication used to treat various inflammatory conditions. Developed by Pfizer Inc., it is a marketed drug. The exact mechanism of tofacitinib is not fully understood, but it is believed to work by inhibiting the activity of certain enzymes in the body. Tofacitinib is used to treat conditions such as rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. It has been shown to be effective in reducing symptoms and improving quality of life for patients with these conditions. However, it can have side effects and may not be suitable for everyone. Overall, tofacitinib is a significant addition to the treatment options available for inflammatory conditions.","brandName":"In open-label phase: treatment with tofacitinib","ecosystem":[],"isGeneric":true,"mechanism":{"target":"Janus kinase 1 (JAK1), Janus kinase 3 (JAK3), and tyrosine kinase 2 (TYK2)","novelty":"best-in-class","modality":"small molecule","drugClass":"Janus kinase inhibitor","explanation":"","oneSentence":"","technicalDetail":"Tofacitinib is a selective inhibitor of Janus kinase 1 (JAK1), Janus kinase 3 (JAK3), and tyrosine kinase 2 (TYK2). It has a high affinity for these enzymes and is able to block their activity with high specificity. This makes it a useful treatment option for patients with inflammatory conditions who have not responded to other therapies."},"_companyIR":{"url":"https://www.pfizer.com/investors","revenueRefs":[],"pipelineRefs":[]},"commercial":{"revenueYear":2025,"annualCostUS":"Generic pricing varies by manufacturer","annualRevenue":1087,"genericStatus":"Generic — off-patent","revenueSource":"SEC 8-K Pfizer (2026-02-03)","revenueCurrency":"USD","peakSalesEstimate":"Not publicly reported","revenueConfidence":"verified (SEC filing)","revenueExtractedAt":"2026-04-01T11:46:09.471949","revenueExtractedBy":"revenue-sec"},"references":[{"id":1,"url":"https://clinicaltrials.gov/search?intr=in-open-label-phase-treatment-with-tofacitinib","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=in-open-label-phase-treatment-with-tofacitinib","fields":["publications"],"source":"PubMed/NCBI"},{"id":3,"url":"https://www.ebi.ac.uk/chembl/","fields":["molecular"],"source":"ChEMBL (EMBL-EBI)"},{"id":4,"url":"https://www.ema.europa.eu/","fields":["regulatoryStatus"],"source":"European Medicines Agency (EMA)"},{"id":5,"url":"https://list.essentialmeds.org/","fields":["regulatoryStatus"],"source":"WHO Essential Medicines List"}],"_tgaChecked":true,"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:56:28.948247+00:00","fieldsConflicting":1,"overallConfidence":0.8},"_whoChecked":true,"biosimilars":[],"competitors":[{"name":"Rituximab","company":"Genentech","advantage":"Rituximab is a monoclonal antibody that targets CD20, similar to tofacitinib's mechanism of action targeting JAK enzymes.","genericName":"Rituximab"},{"name":"Abatacept","company":"Bristol Myers Squibb","advantage":"Abatacept is a selective T-cell costimulation modulator that competes with tofacitinib in the treatment of autoimmune diseases.","genericName":"Abatacept"},{"name":"Baricitinib","company":"Eli Lilly and Company","advantage":"Baricitinib is a JAK1/JAK2 inhibitor that competes with tofacitinib in the treatment of rheumatoid arthritis.","genericName":"Baricitinib"}],"genericName":"in-open-label-phase-treatment-with-tofacitinib","indications":{"approved":[{"name":"Rheumatoid Arthritis","regulator":"FDA"},{"name":"Psoriatic Arthritis","regulator":"FDA"},{"name":"Polyarticular Juvenile Idiopathic Arthritis","regulator":"FDA"},{"name":"Ulcerative Colitis","regulator":"FDA"},{"name":"Psoriasis","regulator":"FDA"},{"name":"Atopic Dermatitis","regulator":"FDA"}],"offLabel":[],"pipeline":[]},"_mhraChecked":true,"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT07281456","phase":"PHASE2","title":"Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren Disease","status":"RECRUITING","sponsor":"National Institute of Dental and Craniofacial Research (NIDCR)","startDate":"2025-12-18","conditions":"Sjogren's Syndrome","enrollment":60},{"nctId":"NCT06095128","phase":"PHASE4","title":"A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)","status":"RECRUITING","sponsor":"Takeda","startDate":"2024-06-12","conditions":"Ulcerative Colitis","enrollment":65},{"nctId":"NCT03000439","phase":"PHASE3","title":"A Safety, Efficacy And Pharmacokinetics Study Of Tofacitinib In Pediatric Patients With sJIA","status":"COMPLETED","sponsor":"Pfizer","startDate":"2018-05-10","conditions":"Arthritis Juvenile Idiopathic","enrollment":100},{"nctId":"NCT06887127","phase":"PHASE3","title":"A Long-term Extension Clinical Study of TLL-018 in Patients With Rheumatoid Arthritis","status":"RECRUITING","sponsor":"Hangzhou Highlightll Pharmaceutical Co., Ltd","startDate":"2025-03-10","conditions":"Rheumatoid Arthritis","enrollment":350},{"nctId":"NCT05580042","phase":"PHASE1","title":"Study to Evaluate the Safety and Tolerability of AC-1101 Topical Gel in Patients with Granuloma Annulare","status":"COMPLETED","sponsor":"TWi Biotechnology, Inc.","startDate":"2022-10-03","conditions":"Granuloma Annulare","enrollment":13},{"nctId":"NCT04311567","phase":"PHASE4","title":"Effects of Tofacitinib vs Methotrexate on Rheumatoid Arthritis Interstitial Lung Disease","status":"TERMINATED","sponsor":"Vastra Gotaland Region","startDate":"2020-11-07","conditions":"Rheumatoid Arthritis, Interstitial Lung Disease Due to Systemic Disease (Disorder), RA","enrollment":3},{"nctId":"NCT04552197","phase":"PHASE1","title":"A Study of JNJ-64251330 in Healthy Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2020-09-02","conditions":"Healthy","enrollment":36},{"nctId":"NCT04610476","phase":"PHASE3","title":"Impact of Tapering Immunosuppressants on Maintaining Minimal Disease Activity in Adult Subjects With Psoriatic Arthritis","status":"UNKNOWN","sponsor":"University of Erlangen-Nürnberg Medical School","startDate":"2020-10-19","conditions":"Psoriatic Arthritis, Withdrawal, Reduction","enrollment":270},{"nctId":"NCT02092467","phase":"PHASE4","title":"Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2014-03-14","conditions":"Arthritis, Rheumatoid","enrollment":4372},{"nctId":"NCT04338711","phase":"PHASE1","title":"A Study In Adult Healthy Volunteers To Asses Once Daily (QD) Dosing With The Selected Age-Appropriate Modified Release (MR) Formulations","status":"COMPLETED","sponsor":"Pfizer","startDate":"2020-06-17","conditions":"Healthy","enrollment":23},{"nctId":"NCT02831855","phase":"PHASE4","title":"Methotrexate Withdrawal Study of Tofacitinib Modified Release Formulation in Subjects With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2016-09-01","conditions":"Rheumatoid Arthritis","enrollment":694},{"nctId":"NCT03112148","phase":"PHASE1","title":"PK Study in Adult Healthy Volunteers to Assess QD Dosing With the Selected Age-appropriate MR Formulations","status":"COMPLETED","sponsor":"Pfizer","startDate":"2017-09-11","conditions":"Healthy","enrollment":24},{"nctId":"NCT01163253","phase":"PHASE3","title":"A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis","status":"TERMINATED","sponsor":"Pfizer","startDate":"2010-09","conditions":"Psoriasis","enrollment":2867},{"nctId":"NCT00263328","phase":"PHASE2","title":"Extension Study Of Stage 1 Subjects Of Study A3921009 For The Prevention Of Acute Rejection In Kidney Transplant Patient","status":"COMPLETED","sponsor":"Pfizer","startDate":"2005-12","conditions":"Kidney Transplantation","enrollment":46},{"nctId":"NCT00106639","phase":"PHASE2","title":"A 6-Month Study Of CP-690,550 Versus Tacrolimus In Kidney Transplant Patients","status":"COMPLETED","sponsor":"Pfizer","startDate":"2005-05","conditions":"Kidney Transplantation","enrollment":61},{"nctId":"NCT01745055","phase":"PHASE1","title":"Co-Administration Of Methotrexate And CP-690,550","status":"COMPLETED","sponsor":"Pfizer","startDate":"2005-04","conditions":"Rheumatoid Arthritis","enrollment":12},{"nctId":"NCT01499004","phase":"PHASE1","title":"A Phase 1 Study To Evaluate The Pharmacokinetics And Safety Of Three Modified Release And One Immediate Release Formulations Of Tofacitinib (CP-690,550) In Healthy Volunteers","status":"COMPLETED","sponsor":"Pfizer","startDate":"2011-11","conditions":"Healthy","enrollment":30},{"nctId":"NCT01202240","phase":"PHASE1","title":"Effect Of Ketoconazole On The Pharmacokinetics Of Tasocitinib (CP-690,550) In Healthy Volunteers","status":"COMPLETED","sponsor":"Pfizer","startDate":"2010-09","conditions":"Healthy","enrollment":12},{"nctId":"NCT01204112","phase":"PHASE1","title":"Estimate The Effect Of Repeat-Dose Rifampin On The Pharmacokinetics Of CP-690,550 In Healthy Volunteers","status":"COMPLETED","sponsor":"Pfizer","startDate":"2010-09","conditions":"Healthy","enrollment":12},{"nctId":"NCT01137708","phase":"PHASE1","title":"CP-690,550 And Oral Contraception Drug-Drug Interaction Study","status":"COMPLETED","sponsor":"Pfizer","startDate":"2010-06","conditions":"Healthy","enrollment":20},{"nctId":"NCT00902460","phase":"PHASE1","title":"CP-690,550 and Midazolam Drug-Drug Interaction Study","status":"COMPLETED","sponsor":"Pfizer","startDate":"2009-06","conditions":"Healthy Volunteer","enrollment":25}],"_emaApprovals":[{"date":"","name":"In open-label phase: treatment with tofacitinib","status":"Authorised","regulator":"EMA"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"molecularData":{"oral":true,"chemblId":"CHEMBL2103743","moleculeType":"Small molecule","molecularWeight":"504.50"},"_patentsChecked":true,"_warningLetters":[{"date":"03/28/2023","subject":"11/07/2022\tTodos Medical Ltd aka Todos Medical USA Inc\tCenter for Food Safety and Applied Nutrition"},{"date":"03/27/2026","subject":"Feedback form"}],"crossReferences":{"chemblId":"CHEMBL2103743"},"formularyStatus":[],"_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[],"publicationCount":0,"therapeuticAreas":["Immunology"],"_revenueScrapedAt":"2026-04-01 10:46:09.497268+00","biosimilarFilings":[],"recentPublications":[],"_drugWebsiteChecked":true,"_healthCanadaChecked":true,"companionDiagnostics":[],"_genericFilersChecked":true,"genericManufacturerList":[],"phase":"marketed","status":"approved","companyName":"Pfizer","companyId":"pfizer","modality":"small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":6,"regulatoryByCountry":[{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":1,"withResults":1},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:56:28.948247+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}